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Traditionally, new clinical guidelines of Diabetes 
Poland are issued at the beginning of the year. The 
current guidelines of our Society, similarly to those 
developed by other Societies, take into account signi-
ficant changes in the philosophy of treatment of type 2 
diabetes and individualization of therapy that goes 
beyond the glucocentric approach. The key issue deter-
mining the choice of an antidiabetic drug has become 
whether the patient is suffering from cardiovascular 
or kidney disease or not. The preferred drug for treat-
ment intensification (add-on to metformin) in patients 
with these diseases should be a GLP-1 analogue or an 
SGLT2 inhibitor, as these drugs provide many benefits 
in the field of cardiovascular and kidney protection, in 
addition to reducing blood glucose per se.
I would also like to draw your attention to the 
topics discussed in this issue of “Clinical Diabetology”. 
Although more than 3,500 years have passed since the 
first description of the symptoms of diabetes in the 
Egyptian papyrus dated to around 1550 BC, diabetes is 
still an incurable disease and insulin therapy is the most 
effective method of decreasing blood glucose. Insulin is 
indispensable in the treatment of type 1 diabetes and 
is necessary in many cases of type 2 diabetes. Almost 
100 years have passed since the discovery and first use 
of insulin. Behind us are years of research aimed at mi-
micking the body’s physiological response to glycemic 
excursions and optimizing insulin therapy.
Over the last decades, there has been significant 
progress in devices supporting the treatment of dia-
betes, such as more and more technically advanced 
subcutaneous insulin pumps and continuous glucose 
monitoring systems that, on the one hand, improve gly-
cemic control, and on the other hand, reduce the risk of 
hypoglycemic episodes and thus improve the patient’s 
comfort of life. What is even more important, this also 
translates into a reduction in the risk of development 
and progression of chronic vascular complications of 
diabetes, which are still a key clinical problem of modern 
diabetology. One of such devices, the FreeStyle LIBRE 
continuous blood glucose monitoring system, was eva-
luated by a remarkable group of experts in the current 
edition of “Clinical Diabetology”. Worth reading are also 
two articles providing a theoretical supplement to the 
discussion on continuous glycemic monitoring systems: 
a review paper discussing the measurement of glucose 
in the interstitial fluid and a report from Diabetes Inno-
vations Day, a meeting dedicated to diabetes innovations 
and their use by physicians and patients that was held 
on 23–24 November 2018 in Poznan. Another important 
topic is diabetes occurring in pregnant women and its 
impact on a child as well as the woman herself and her 
future risk of developing type 2 diabetes. In this aspect, 
I encourage you to read an original paper assessing the ef-
fect of breastfeeding on carbohydrate metabolism among 
women with a history of gestational diabetes. A constant 
element in the development of “Clinical Diabetology” is 
the publication of articles sent by foreign authors. This 
issue includes a very interesting article that will expand our 
knowledge about the diagnosis of type 1 diabetes in India.
At the end, I would like to thank you for all the 
articles sent to us and encourage you to further coope-
ration. See you in Lublin at the 20th Scientific Congress 
of Diabetes Poland.
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